Chronic demyelinating polyneuropathies

JA Allen - CONTINUUM: Lifelong Learning in Neurology, 2017 - journals.lww.com
JA Allen
CONTINUUM: Lifelong Learning in Neurology, 2017journals.lww.com
Abstract Purpose of Review: This article reviews the chronic demyelinating neuropathies,
with a focus on the diagnosis and treatment of immune-mediated neuropathies and the
features that can help differentiate immune-mediated neuropathies from other chronic
demyelinating peripheral nerve conditions. Recent Findings: Advances in clinical
phenotyping and outcomes assessment have enabled neurologists to improve disease
recognition, treatment, and disease monitoring. Our understanding of the …
Abstract
Purpose of Review: This article reviews the chronic demyelinating neuropathies, with a focus on the diagnosis and treatment of immune-mediated neuropathies and the features that can help differentiate immune-mediated neuropathies from other chronic demyelinating peripheral nerve conditions.
Recent Findings: Advances in clinical phenotyping and outcomes assessment have enabled neurologists to improve disease recognition, treatment, and disease monitoring. Our understanding of the immunopathogenesis of demyelinating neuropathies is evolving. Identification of new antibodies and recognition that node of Ranvier dysfunction may be an early pathogenic feature may herald further diagnostic and treatment advancements.
Summary: The chronic demyelinating polyneuropathies are heterogeneous. The clinical and diagnostic features are sometimes overlapping, and the specific disorders are variable in pathogenesis, treatment, and prognosis. This heterogeneity underscores the importance of achieving diagnostic accuracy and implementing disease-specific treatment approaches.
Lippincott Williams & Wilkins